Skip to main content
. 2018 Jan 3;18:11. doi: 10.1186/s12885-017-3955-4

Fig. 4.

Fig. 4

Overall survival according to anti-EGFR/anti-VEGF based therapy and TP53 mutation status in metastatic colorectal cancer. Kaplan-Meier curves for overall survival in TP53 mutant (a) or TP53 wild-type (b) disease with first-line anti-EGFR or anti-VEGF based therapy. HR is hazard ratio, 95% confidence interval in brackets